Psoriasis - Clinical Features and Classification

Clinical Presentation and Severity Assessment of Psoriasis Introduction Psoriasis is a chronic skin disorder characterized by well-defined, inflamed patches that can significantly impact patients' physical health and quality of life. Understanding how psoriasis presents clinically is essential for diagnosis, and recognizing its severity helps guide treatment decisions. Additionally, psoriasis is not just a skin condition—it's associated with several serious systemic comorbidities that require clinical attention. Characteristic Skin Findings Psoriasis presents with distinctive visual and clinical features. The hallmark lesion is a well-demarcated, erythematous (red) plaque with silvery scales. These plaques commonly appear on areas of mechanical stress or trauma, particularly the elbows, knees, scalp, and lower back. Clinically, patients often report that lesions are itchy and painful. A key diagnostic sign is the Auspitz's sign, which occurs when scales are removed and the lesion bleeds. This happens because of the thinning of the epidermis directly over the inflamed dermal tissue. Another important clinical sign is the Koebner phenomenon (also called the isomorphic response), where new psoriatic lesions develop at sites of skin trauma, such as scratches, cuts, or burns. This can occur within 7-14 days of injury and is pathognomonic (characteristic) of psoriasis. Forms of Psoriasis Psoriasis is classified into several morphological types, each with distinct clinical features: Plaque Psoriasis is the most common form (approximately 80-90% of cases) and presents with the characteristic large, well-demarcated plaques with silvery scales described above. Pustular Psoriasis presents differently—lesions are surrounded by red, tender skin and contain small pustules (pus-filled bumps). It commonly affects the palms and soles in a pattern called palmoplantar pustulosis. This form can be localized or generalized, and the generalized form represents a medical emergency. Seborrheic-like Psoriasis shows red plaques with greasy (rather than silvery) scales. These lesions appear in areas of high sebum production, particularly the scalp, forehead, and other facial areas. The greasy appearance can make this form confused with seborrheic dermatitis. <extrainfo> Other Forms: Psoriasis also presents in guttate (small drop-like lesions, often after streptococcal infection), inverse (occurring in skin folds), napkin (in infants in the diaper area), and oral forms, though these are less common. </extrainfo> Assessing Psoriasis Severity Determining severity is critical because it guides treatment decisions and predicts impact on patient functioning. Severity is defined using three main criteria, and meeting any one of them classifies psoriasis as moderate to severe: Body Surface Area (BSA) Involvement: This is the percentage of total skin affected by psoriasis. Mild: ≤ 10% BSA Moderate to Severe: > 10% BSA Psoriasis Area and Severity Index (PASI): This combines the extent of involvement with the severity of individual lesions. The score ranges from 0 (no disease) to 72 (maximal disease). A PASI of 10 or less indicates mild disease, while greater than 10 indicates moderate to severe disease. Dermatology Life Quality Index (DLQI): This is a 10-question validated tool assessing how much psoriasis impacts daily life. Each question is scored 0-3, giving a total range of 0-30. Higher scores indicate greater impact on functioning: Mild: DLQI ≤ 10 Moderate to Severe: DLQI > 10 The key concept here is that severity reflects both the physical extent of disease and its functional impact on the patient. A patient with limited plaques but severe psychological distress would be classified as moderate to severe based on their DLQI score alone. Systemic Comorbidities An important clinical concept is that psoriasis is associated with numerous systemic diseases, suggesting that psoriasis involves dysregulation beyond just the skin. Cardiovascular Disease: Patients with psoriasis have a 2.2-fold higher risk of myocardial infarction, stroke, and other cardiovascular events compared to the general population. This increased risk exists even after adjusting for traditional cardiovascular risk factors, suggesting that the inflammatory state of psoriasis itself contributes to vascular disease. Type 2 Diabetes: Psoriasis increases the risk of developing type 2 diabetes by approximately 1.5 times. The mechanism likely involves systemic inflammation and metabolic dysfunction associated with psoriasis. Mental Health Disorders: Between 28-55% of individuals with psoriasis experience depression or depressive symptoms. This is higher than the general population and reflects both the visible nature of the disease and the chronic inflammatory state. The bidirectional relationship between psoriasis and depression—where each can worsen the other—makes mental health assessment an important part of patient care. Other Systemic Associations: Psoriasis is linked to increased incidence of: Psoriatic arthritis (joint inflammation affecting 10-30% of psoriasis patients) Lymphomas Crohn's disease <extrainfo> These associations suggest that psoriasis may involve a shared genetic predisposition or common inflammatory pathways that affect multiple organ systems. Understanding these comorbidities helps explain why psoriasis requires comprehensive management beyond topical skin treatments. </extrainfo> Clinical Significance The presence of comorbidities changes how psoriasis is managed. Patients require screening for cardiovascular disease, metabolic disorders, and mental health conditions. More importantly, the severity classification discussed earlier determines not just the intensity of treatment, but also whether systemic (whole-body) therapies are appropriate—as you'll learn in subsequent sections on management.